Nurse-led hepatocellular carcinoma surveillance clinic provides an effective method of monitoring patients with cirrhosis by Nazareth, Saroja et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
2016 
Nurse-led hepatocellular carcinoma surveillance clinic provides an 
effective method of monitoring patients with cirrhosis 
Saroja Nazareth 
Edith Cowan University 
Nadine Leembruggen 
Edith Cowan University 
Rhoda Tuma 
Edith Cowan University 
Sook-ling L. Chen 
Edith Cowan University 
Samarth Rao 
Edith Cowan University 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Diseases Commons, and the Other Nursing Commons 
10.1111/ijn.12472 
Nazareth, S., Leembruggen, N., Tuma, R., Chen, S., Rao, S., Kontorinis, N., & Cheng, W. (2016). Nurse-led 
hepatocellular carcinoma surveillance clinic provides an effective method of monitoring patients with cirrhosis. 
International Journal of Nursing Practice, 22, 3-11. Available here 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/2164 
Authors 
Saroja Nazareth, Nadine Leembruggen, Rhoda Tuma, Sook-ling L. Chen, Samarth Rao, Nickolas Kontorinis, 
and Wendy Chen 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/2164 
ORIG INAL ART ICLE
Nurse-led hepatocellular carcinoma surveillance
clinic provides an effective method of monitoring
patients with cirrhosis
Saroj Nazareth, RN
Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia
School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia
Nadine Leembruggen
Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia
School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia
Rhoda Tuma, RN
Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia
School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia
Sook-Ling Chen, RN
Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia
School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia
Samarth Rao
Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia
School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia
Nick Kontorinis
Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia
School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia
Wendy Cheng, MD
Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia
School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia
Nazareth S, Leembruggen N, Tuma R, Chen S-L, Rao S, Kontorinis N, Cheng W. International Journal of Nursing
Practice 2016; 22: (Suppl. 2), 3–11
Nurse-led hepatocellular carcinoma surveillance clinic provides an effective method of
monitoring patients with cirrhosis
Correspondence: Nadine Leembruggen, Department of Gastroenterology and Hepatology, Royal Perth Hospital, Level 4 South Block, Wellington Street,
Perth WA 6000, Australia. Email: nadine.leembruggen@health.wa.gov.au
International Journal of Nursing Practice 2016; 22: (Suppl. 2), 3–11
doi:10.1111/ijn.12472 © 2016 John Wiley & Sons Australia, Ltd
bs_bs_banner
The aim of this study is to examine the acceptability and effectiveness of a nurse-led hepatocellular carcinoma (HCC)
surveillance clinic in high-risk patients with cirrhosis/advanced fibrosis. Early detection of HCC is associated with better
treatment outcomes and improved survival. International guidelines recommend 6-monthly surveillance of patients at
risk of developing HCC. A nurse-led HCC surveillance protocol was established to support patients in adherence to
surveillance protocols. The design used was retrospective document analysis. Retrospective analysis of healthcare records
of patients referred to the clinic between August 2009 and December 2015. Extracted data included attendance of
clinic visits, blood testing, ultrasound or other imaging, and outcomes. Ultrasound was attended within 6months in
30.3% of cases and within 7months in 71.2% of cases. The median time between Nurse-Led Clinic appointments,
ultrasound scans and blood testing did not exceed 9months. First year FibroScans were attended by 82.9% (63/76)
patients; endoscopy was indicated for 42 and attended by 35 (83.3%) patients. Lesions were identified in 16 patients
(21.5%) and HCC diagnosed in two patients. One patient died because of HCC and one to sub-dural haematoma.
Nurse-led HCC surveillance was an effective method of monitoring patients with cirrhosis at high risk of developing
HCC. Well-defined protocols enable timely identification of patients with HCC or hepatic decompensation so that
management strategies can be implemented without delay. The potential benefits identified by this study warrant fur-
ther, rigorous evaluation.
Key words: cirrhosis, HCC screening, hepatocellular carcinoma, nurse-led programme, surveillance.
INTRODUCTION
Hepatocellular carcinoma (HCC) has long been identified as
a major cause of liver-related deaths in patients with com-
pensated cirrhosis.1 Various aetiological factors such as per-
sistent hepatitis B (HBV) or hepatitis C virus (HCV),
infection, alcohol and cirrhosis are related to development
of HCC.1–5 Despite successful clearance of hepatitis virus,
the risk of HCC remains significant,6 particularly in patients
with advanced fibrosis and cirrhosis.
Early detection of HCC is associated with better treat-
ment outcomes and improved survival.7–9 As HCC is
asymptomatic in the early stages, a surveillance programme
is essential for its early detection. The American Association
for the Study of Liver Diseases (AASLD), the European As-
sociation for the Study of the Liver (EASL) and the Asian
Pacific Association for the Study of the Liver (APASL)
guidelines recommend HCC surveillance using ultrasound,
on a 6-monthly basis for high-risk patients, who have been
identified as comprising:
• patients with advanced fibrosis and cirrhosis
• patients with HBV infection who meet the following
criteria:
Asian males > 40years of age,
Asian females > 50years of age,
patients of African origin > 20years of age
patients with a positive family history of HCC.2,10,11
The Royal Perth Hospital Nurse-led HCC Surveillance
Clinic (Nurse-Led Clinic) was established in 2005. The
clinic was established in response to concerns raised by
clinicians that their patients were not attending scheduled
surveillance, and that the Medical Hepatology Clinic did
not have the capacity to follow up on non-attendance.
The Nurse-Led Clinic was designed to focus on patient ad-
herence to surveillance and to reduce the surveillance work-
load of medical staff.
STUDY METHODS
Study aims
The purpose of the study was to evaluate whether a Nurse-
Led Clinic can provide an effective programme for the iden-
tification of patients with early HCC or impending hepatic
decompensation.
The first aim was to examine whether the Nurse-Led
Clinic could facilitate attendance for monitoring in line with
guideline recommendations: every 6months for clinical as-
sessment, ultrasound and pathology; yearly for FibroScan.
The second aim was to examine whether the clinic was ef-
fective at timely identification of patients with early HCC or
impending hepatic decompensation.
The nurse-led clinic
Clinic patients
Patients with cirrhosis or advanced fibrosis were referred by
doctors in the Medical Hepatology Clinic to the Nurse-Led
Clinic (Fig. 1). Eligibility criteria for the Nurse-Led Clinic
aligned with published guidelines2,10,11 to include:
• Patients with well-compensated liver disease with no
history of HCC
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• Patients with advanced fibrosis or cirrhosis, defined as a
METAVIR score of F3 or F4 on liver biopsy, liver ;stiff-
ness of ≥ 10kPa on FibroScan, a HepaScore® of ≥ 0.8,
ultrasound evidence of cirrhosis or portal hypertension
• Patients with hepatitis B without cirrhosis or advanced
cirrhosis were also included if they were:
► Asian males ≥ 40years of age,
► Asian females ≥ 50years of age,
► Africans ≥ 20years of age or
► Had a family history of HCC, in alignment with pub-
lished guidelines.2,10,11
The HCC surveillance protocol was established to enable
identification and fast-tracking for urgent medical review of
patients with either HCC or hepatic decompensation.
Clinic processes
The nurse arranged 6-monthly clinic visits, ultrasounds and
laboratory tests, including for alpha-fetoprotein (AFP). En-
doscopic variceal surveillance was arranged as per protocol,
specific to the needs of each patient (for example, yearly,
two-yearly or not required). Following the introduction
of transient elastography (FibroScan™) at Royal Perth Hos-
pital in 2012, patients were also referred for baseline and
annual FibroScans. Clinic visits included an assessment for
physical signs of progressive liver disease (e.g. ascites, jaun-
dice, encephalopathy), review of ultrasound, pathology,
FibroScan and endoscopy findings. Routine pathology tests
included liver function tests, urea and electrolytes, full
blood count, international normalized ratio (INR) and
AFP. Patients with impaired hepatic synthetic function, in-
cluding those with INR levels above the upper limit of nor-
mal or albumin below the lower limit of normal, those with
changes on ultrasound including the identified lesions or
with elevated levels of AFP were discussed with medical
staff and either appropriate management or referral back
to the medical clinic instituted. Patients could also be re-
ferred back to the medical clinic if the nurse had any other
concerns about the patient.
Management plans
All patients with clinically significant abnormalities were
notified to the Hepatology Fellow or consultants, who im-
mediately arranged appropriate follow-up testing (e.g. a
computed tomography [CT] or magnetic resonance imaging
[MRI] scan in patients with clinically significant changes on
ultrasound). Each case of concern was presented at a fort-
nightly Multidisciplinary HCC Meeting, which included ra-
diologists, hepatologists, nurses and surgeons. When HCC
was identified or suspected, a management plan was
established for the patient by the multidisciplinary team
and the patient was discharged from the Nurse-Led Clinic
and returned to the medical clinic for management. Poten-
tial treatment modalities for patients with HCC included
transcatheter arterial chemoembolization (TACE),
radiofrequency ablation (RFA), microwave ablation, selec-
tive internal radiation therapy (SIRT), surgery, referral
for orthotopic liver transplantation (OLT) or other treat-
ment, as appropriate.
Sample/participants
To be eligible for inclusion in this evaluation patients had to
have met eligibility criteria (described previously) and been
referred to the Nurse-Led Clinic.
Figure 1. Flow chart of patient referrals
within the surveillance system. Abbreviations:
AFP, alpha-fetoprotein; HCC, hepatocellular
carcinoma; INR, international normalized ratio;
LLN, lower limit of normal; ULN, upper limit
of normal.
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Data collection
The healthcare records of all patients referred to the Nurse-
Led Clinic between August 2009 and December 2015 were
reviewed and relevant data extracted. Data for complete
years 2010–2015 were analysed. Relevant data for the
analysis included the number of referrals, patient demo-
graphic data, baseline clinical characteristics and medical
history, current treatment, patient attendance for clinic
visits, blood testing, ultrasound, FibroScan and endoscopy
results, outcome of additional imaging (HCC diagnosis),
HCC treatment received and outcome.
Data analysis
Data were analysed using univariate analysis and summa-
rized using descriptive statistics (e.g. range, mean, median,
standard deviation [SD]).
Aim one:To examine whether attendance for monitoring
occurred in line with guideline recommendations,
percentages of patients attending for monitoring in line
with guidelines every 6months with one month
tolerance/one year with one month tolerance (see Fig.
1) from referral were calculated. Because of the com-
plexities of appointments and patient availability, a toler-
ance of one month was added to the maximum of six
months between monitoring appointments recom-
mended by international guidelines.
Aim two:To examine whether the clinic was effective at
timely identification of patients with early HCC or
impending hepatic decompensation, numbers and per-
centages were calculated of those for whom these
diagnoses were identified.
Ethical considerations
The project was approved by the Nursing Safety and Qual-
ity Committee at Royal Perth Hospital.
RESULTS
Patients
A total of 86 patients were referred to the Nurse-Led Clinic
between August 2009 and November 2015. Of these,
medical records were not available for four patients, and
six patients did not attend any Nurse-Led Clinic visits;
therefore, data were extracted from the records of 76 pa-
tients. The numbers of patients referred to the clinic were
generally steady, with an average of approximately 12 pa-
tients (range 7–16) referred annually (Table 1).
Patient demographics and clinical characteristics of the
76 patients with at least one Nurse-Led Clinic attendance
are shown in Table 2. The majority of patients were male
(73.7%). Patients ranged 28–75years of age, with a mean
(SD) age 57 (8.5) years. Mean body weight was 76 (17.5)
kg (range 49–131kg). Underlying liver diseases included
hepatitis C, hepatitis B, alcoholic liver disease (ALD),
non-alcoholic steatohepatitis (NASH) or autoimmune hepa-
titis. A total of 57.9% of patients were assessed as cirrhotic
and 32.9% had advanced fibrosis. Most patients (92%) re-
ported current or past HCV infection. Four patients re-
ceived HCV treatment during surveillance, which
included pegylated interferon/ribavirin/boceprevir in three
patients and pegylated interferon/ribavirin in one patient.
All four patients achieved sustained virologic response
(SVR).
Aim 1: adherence to the monitoring
schedule
Follow-up is ongoing for most patients, with the longest
follow-up duration to date being 64months. Seventy-five
patients attended an initial ultrasound; one patient who
was discharged because of relocation interstate did not at-
tend ultrasound. Sixty two patients attended at least one
follow-up ultrasound. Only 26% of patients (16/62) had
a mean duration between ultrasounds of within 6months,
but 65% of patients (40/62) attended ultrasounds before
7months on average, which was deemed compliant with
international recommendations. No patients had a mean
ultrasound interval of greater than 12months.
The total number of ultrasound scans attended was 339,
of which 264 were follow-up ultrasounds. Overall, 80
follow-up ultrasounds (30.3%) were completed within
6months of the previous ultrasound. With a tolerance of
one month accepted, 188 follow-up ultrasounds (71.2%)
Table 1 Number of patient referrals to the clinic each year
Year of referral 2010 2011 2012 2013 2014 2015
Number of patients 11 16 7 10 13 16
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were completed within less than 7months of the previous
ultrasound. Only 12 (4.5%) were > 1 year apart (Fig. 2).
The mean (SD) duration between ultrasounds ranged 4.98
(2.19) months at the 12th ultrasound to 7.27 (2.66) months
at the 8th ultrasound (Fig. 3). The mean (SD) duration be-
tween Nurse-Led Clinic appointments ranged 4.41 (2.59)
months for Visit 10 to 7.48 (5.27) months for Visit 12.
The mean (SD) duration between blood samples ranged
4.74 (3.76) months for Visit 10 to 8.89 (3.59) months
for Visit 9. The overall median time between Nurse-Led
Clinic appointments, ultrasound scans and blood testing
did not exceed 9months.
FibroScan was a relatively new modality for assessing fi-
brosis. First and second year FibroScans were attended by
82.9% (63/76) and 2.6% (2/76) of patients, respectively.
Endoscopic variceal surveillance was arranged specifi-
cally to meet the needs of each patient and ranged from
no endoscopy (as not required), to a single endoscopy or
repeat endoscopy every 12 or 24months. Overall 55.0%
(42/76) of patients met the criteria for endoscopy (cirrho-
sis with the absence of a prior endoscopy confirming no
further endoscopy required) and 35 of these 42 patients
(83.3%) attended an initial endoscopy. Of the seven
who did not attend, three relocated, one was discharged
from the Nurse-Led Clinic, one refused the procedure
and two patients did not attend. Second, third and fourth
endoscopies were attended by 10, 7 and 4 patients
respectively.
In total 15 patients were discharged from the Nurse-
Led Clinic. Reasons for discharge included HCC surveil-
lance no longer required (n=6), referral to the Gastroen-
terology Medical Clinic for follow-up of a pancreatic
lesion (n=1), HCC ablation (n=1), deceased (n=2), lost
to follow up (n=1), patient decision (n=1) and referral
to a treatment programme (n=1). Two patients with
HBV were referred to the Nurse-Led Clinic but returned
to the Medical Clinic for concurrent HBV treatment. To
date 51 patients (62%) continue to be monitored regularly
in the Nurse-Led Clinic.
Aim 2: timely detection of deterioration
and complications
Referrals for additional imaging were made for 13 patients
(17.1%) for CT and 5 patients (6.6%) for MRI. The rea-
sons for referral were predominantly derived from the
regular ultrasound investigations, and, for CT, included
hepatic lesions (n=6); hyperechoic hepatic nodules/foci
(n=3); hypoechoic foci in the spleen (n=1); acute
Table 2 Baseline demographics and clinical characteristics of pa-
tients who attended at least one Nurse-Led Clinic visit
n (%) N=76
Gender
Male 56 (73.7)
Female 20 (26.3)
Current/past substance use†
None 35 (46.1)
Alcohol 29 (38.2)
Tobacco 20 (26.3)
Marijuana 11 (14.5)
IVDU 10 (13.2)
Unknown 4 (5.3)
Liver disease
HBV 2 (2.6)
HCV past 50 (65.8)
HCV current 20 (26.3)
NASH 2 (2.6)
ALD 2 (2.6)
Fibrosis stage
Early fibrosis 4 (5.3)
Advanced fibrosis 25 (32.9)
Cirrhosis 44 (57.9)
Unknown 1 (1.3)
Initial assessment of fibrosis
Liver biopsy 30 (39.5)
Ultrasound 8 (10.5)
HepaScore 24 (31.6)
FibroScan 13 (17.1)
Clinical 1 (1.3)
History of decompensation 5 (6.6)
Signs of chronic liver disease 2 (2.6)
Comorbidities
Any 49 (64.47)
Psychiatric 10 (13.2)
T2DM 9 (11.8)
HIV 4 (5.3)
Child-Pugh score
5 73 (96.1)
6 1 (1.3)
7 1 (1.3)
Unknown 1 (1.3)
†Some patients had multiple substance use. ALD, alcoholic
liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus;
HIV, human immunodeficiency virus infection; IVDU, intravenous
drug use; NASH, non-alcoholic steatohepatitis; T2DM, type 2
diabetes mellitus.
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(right-sided) abdominal pain, nausea, vomiting and diar-
rhea (n=1); previous possible evidence of HCC (n=1)
and suprahepatic inferior vena cava narrowing (n=1).
The reasons for MRI included hepatic lesions suspicious
of HCC (4), only one of whom had raised AFP and pos-
sible pancreatic lesion (1).
Of the 35 patients who attended the first endoscopy visit,
six patients were found to have oesophageal varices.
Among 16 patients with suspicious lesions, follow-up re-
vealed cyst(s) in eight patients, haemangioma in three pa-
tients, other benign lesions in three patients and HCC in
two patients. The first patient (Patient A) diagnosed with
HCC was a 66-year-old African male with HCV Child-
Pugh class A cirrhosis, METAVIR score of F3/4 (Box A).
Box A: Patient A with HCC
Patient A had received prior treatment with
pegylated interferon/ribavirin, and achieved an
SVR in 2011. As he had advanced liver disease, he
was referred to the Nurse-Led Clinic in February
2011. The patient underwent regular HCC
surveillance with ultrasound and/or CT scans
during follow-up in nurse-led HCC surveillance
clinics and scans were discussed regularly at
Multidisciplinary HCC Meetings.
► An initial hypervascular lesion (< 1 cm) identified in
2009 in segment 6 on CT scan was followed-up
regularly. CT scan was performed because of rise
in alpha-fetoprotein to 140 KIU/L (N< 11KIU/L).
► There were no changes in the lesion on serial imaging
until 2013. In May 2013 a CT scan revealed that the
lesion in segment 6 was suspicious, with classical
arterial enhancement and wash-out in the portal
venous phase.
► An ultrasound in June 2013 showed increase in size of
the lesion to 14×16×17mm, confirming the lesion
in segment 6 as HCC.The patient’s case was
discussed at the Multidisciplinary HCC meeting and
the patient was initially successfully treated with
microwave ablation. However, a CT scan
conducted 5months after ablation showed
recurrence at the same site and the patient
underwent resection. The patient died in July 2014
following admission to hospital with ascites and
widespread metastases, 13months after confirmed
diagnosis of HCC.
The second patient (Patient B) was a 56-year-old male
with HCV Child-Pugh class A cirrhosis. He had been
previously treated with pegylated interferon/ribavirin with
SVR in 2008 (Box B).
DISCUSSION
This evaluation shows that the Nurse-Led Clinic was gener-
ally acceptable to patients and met its primary aim of
retaining patients in a monitoring programme in line with
guideline recommendations. This allowed timely detection
of abnormalities and use of a well-defined pathway of man-
agement of abnormal results which expedited patient man-
agement. Ultrasound was attended within 6months in
Figure 2. Episodes of care for ultrasound
meeting guideline recommendations.
Figure 3. Mean (standard deviation) duration since previous ultrasound
scan.
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30.3% of cases, and within 7months in 71.2% of cases. This
appears better than in published studies where adherence to
surveillance is reported as low as 12%, less than 20%, 22%
and 17.4% with a longer acceptable interval of
12months.12–16 An overall median time between monitor-
ing appointments of less than 9months showed clinically
significant improvement following establishment of the
Nurse-Led Clinic.
Increased patient knowledge and involvement in treat-
ment decisions have been associated with better adherence
to medical recommendations.17 The provision of patient ed-
ucation through the Nurse-Led Clinic might have contrib-
uted to the better patient adherence noted in this study.
NASH and ALD have been associated with poor compli-
ance with surveillance.12,15,18 Because very few patients in
this study had NASH or ALD (two patients each; Table 2
), this might have contributed to the better adherence
achieved compared to these published studies.
Some patients develop widespread disease despite close
surveillance and two cases of HCC were identified through
the Nurse-Led Clinic. Despite the lesion in Patient A being
relatively small when initially confirmed (14×17×16mm)
and successfully treated with microwave ablation at that
site, the patient developed widespread metastases and died
less than 12months later. This might be because of the pres-
ence of other lesions in the liver not detected by imaging
techniques, especially in the diffuse form of HCC. Alterna-
tively the initial lesion, despite its small size, might have al-
ready resulted in metastatic disease. Patient A also had type
2 diabetes mellitus, which has been associated with a greater
risk of developing HCC19, although it is unknown whether
this contributed to the rapid progression of his disease.
These two cases (Patients A and B) highlighted the impor-
tance of HCC surveillance in patients who have been suc-
cessfully treated for hepatitis C. Superimposed factors
such as NASH can also contribute to development of
HCC20,21 even in those patients who had not developed sig-
nificant fibrosis after SVR.
Poor outcome despite surveillance and early detection
has been observed in another study. A Belgian study of
141 patients with cirrhosis undergoing surveillance detected
a total of 6 HCC lesions, all single nodules < 4 cm in size,
yet four patients died 3–15months later (median 8months)
despite treatment with percutaneous acetic acid injection.18
Two of the patients who died had extensive HCC. Despite
these observations, studies have confirmed the usefulness of
surveillance programmes,22,23 for example demonstrating
mean survival duration of 27months for patients diagnosed
in surveillance programmes (95% Confidence Interval (CI)
16.6, 37.4) compared with only 6months (95% CI 2.6,
9.4) among those diagnosed outside of a surveillance pro-
gramme (p=0.001).23 This is reflected in the current study
where the mean duration of follow-up in the Nurse-Led
Clinic is currently 23.6months. Only two deaths have
occurred in the Nurse-Led Clinic from its inception in
2005 until the present day and 62% of the patients enrolled
in this clinic remain in follow-up.
This study is limited by its retrospective nature and re-
liance upon routinely collected health service data, but this
is a cost-effective approach for an initial evaluation. The
positive results demonstrated to date indicate that a
nurse-led HCC surveillance programme has the potential
to ensure that HCC is detected earlier with better
outcomes for patients. An additional benefit accrued from
reduced surveillance workload of medical staff, enabling
them to focus on treatment of patients with more severe
and complex problems.
CONCLUSIONS
This retrospective analysis provided an evaluation demon-
strating that a nurse-led HCC surveillance clinic is an ac-
ceptable and effective method of monitoring patients with
cirrhosis who are at high risk of developing HCC, and of re-
ducing the surveillance workload of medical staff. Well-
defined protocols enable timely identification of patients
with HCC or hepatic decompensation so that management
strategies can be implemented without delay.
The potential benefits identified by this study warrant
further, rigorous evaluation: a formal randomized trial of
the two models of surveillance with cost-effectiveness
analysis to detail the economic effects of nurse-led versus
medical surveillance models. Detailed exploration of the
patients’ perspectives is also needed, to fully understand
what elements of the Nurse-Led Clinic attract and retain
these patients within this programme.
Box B: Patient B with HCC
Patient B experienced oesophageal variceal bleeding
in 2009. The varices were successfully eradicated,
and the patient was referred to the Nurse-Led
Clinic in August 2010. In March 2013, a
21×25×23mm lesion was detected in segment 6
by ultrasound and the patient underwent CT and
MRI scans. He was successfully treated with TACE.
At his latest follow-up in September 2015, MRI
showed no recurrence of the lesion.
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